Pfitzmann Robert, Benscheidt Birgit, Langrehr Jan Michael, Schumacher Guido, Neuhaus Ruth, Neuhaus Peter
Department of Surgery, Charité, Campus Virchow-Klinikum, Humboldt-University Berlin, Germany.
Liver Transpl. 2007 Feb;13(2):248-57. doi: 10.1002/lt.20904.
Compared to primary liver transplantation (LT), the inferior results in the outcome of liver retransplantation (re-LT) continue to be a major challenge. The purpose of this study was to analyze changes in and outcomes of re-LT over a period of 15 years at the Charité Virchow Clinic. Between 1989 and 2003, we performed 1,619 LTs and 157 re-LTs (9.7%) in 1,462 patients. A total of 119 retransplants (50 females, 69 males) were analyzed after consideration of exclusion criteria: recipient age <16 years, second re-LT, primary LT as split-liver or living-related LT, or combination with renal transplantation or Whipple operation. All patients received a whole-size organ. Mean follow-up was 62 months (6 days to 187 months). The main indications for re-LT were initial nonfunction (26.9%), recurrence of viral-induced hepatitis (20.2%), or acute and chronic rejection or thrombosis of the hepatic artery (both 16.8%). The main causes of death were bacterial infections (26.0%) as well as bleeding complications or recurrence of disease (both 16.0%) within the first postoperative month. Overall, 50 out of 119 patients (42%) died after re-LT, 26 patients within the first 3 months and 38 within 1 year. Overall patient survival was 89.9% after 1 month, 78.2% after 1 year, and 67.1% after 5 years. In conclusion, our study showed good clinical results after re-LT. Apart from the changing indications for re-LT with an increasing amount of initial organ failure and hepatic artery thrombosis, the analysis also showed a decreasing amount of complications such as rejection, ischemic type biliary lesions, and recurrence of the disease with unchanged outcome over a period of 15 years.
与初次肝移植(LT)相比,肝再次移植(re-LT)效果较差仍是一个重大挑战。本研究的目的是分析在夏里特·维尔肖诊所15年间肝再次移植的变化情况及结果。1989年至2003年期间,我们对1462例患者进行了1619例肝移植和157例再次肝移植(9.7%)。在考虑排除标准后,对总共119例再次移植患者(50例女性,69例男性)进行了分析:受者年龄<16岁、第二次再次肝移植、初次肝移植为劈离式肝移植或活体亲属供肝移植、或合并肾移植或惠普尔手术。所有患者均接受了全尺寸器官。平均随访时间为62个月(6天至187个月)。再次肝移植的主要适应证为原发性无功能(26.9%)、病毒诱导性肝炎复发(20.2%)、急性和慢性排斥反应或肝动脉血栓形成(均为16.8%)。主要死亡原因是细菌感染(26.0%)以及术后第一个月内的出血并发症或疾病复发(均为16.0%)。总体而言,119例患者中有50例(42%)在再次肝移植后死亡,26例在术后3个月内死亡,38例在1年内死亡。术后1个月总体患者生存率为89.9%,1年时为78.2%,5年时为67.1%。总之,我们的研究显示肝再次移植后临床效果良好。除了随着原发性器官功能衰竭和肝动脉血栓形成数量增加,再次肝移植的适应证发生变化外,分析还显示在15年期间,诸如排斥反应、缺血性胆管病变和疾病复发等并发症数量减少,而结果未变。